lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
LB Pharmaceuticals Inc
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
May 7, 2026
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
May 4, 2026
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
May 3, 2026
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
May 3, 2026
LB Pharmaceuticals to Participate in Upcoming March Investor Events
April 30, 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 9, 2026
LB Pharmaceuticals Announces $100.0 Million Private Placement
March 9, 2026
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
January 26, 2026
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
January 21, 2026